FTSE 250 movers: BTG climbs on full-year sales outlook
3rd Apr 2014 15:31
Specialist healthcare group BTG rose strongly after saying it expects full-year sales to be at the top end of guidance after a 'transformational year'. Revenues for the financial year to March 31st are expected to be at the upper end of the £275-285m guidance range, which the company had reiterated
Read moreLondon midday: Gains erased with investors nervous ahead of ECB
3rd Apr 2014 12:05
- ECB in focus ahead of policy meeting - UK services PMI slips, US data ahead - Tullow and Standard Life upgraded - BSkyB drops on HSBC comments - Just Eat impresses with IPO techMARK 2,776.98 -0.21% FTSE 100 6,657.60 -0.02% FTSE 250 16,390.84 -0.15% It was a choppy morning for UK equity markets o
Read moreLondon open: Trading cautious ahead of ECB decision
3rd Apr 2014 08:46
- ECB meeting the main event of the day - China unveils 'mini-stimulus' - Global economic data in focus - Tullow, Standard Life upgraded - Kingfisher rises on Mr Bricolage deal techMARK 2,780.50 -0.09% FTSE 100 6,663.30 +0.06% FTSE 250 16,387.30 -0.17% UK stocks edged higher on Thursday morning, b
Read moreBTG annual sales to be at top end of guidance
3rd Apr 2014 07:43
Specialist healthcare group BTG expects full-year sales to be at the top end of the guidance after a 'transformational year'. Revenues for the financial year to March 31st are expected to be at the upper end of the £275-285m guidance range, which the company had reiterated as recently as January. T
Read moreFTSE 250 movers: BTG slides following broker comments
29th Jan 2014 15:45
Healthcare company BTG was a heavy faller despite saying trading for the four months to January 28th had been in line with expectations. The group was hit by comments from finnCap and N+1 Singer, which both reitered their 'sell' rating on the stock. The group, which develops products targeting crit
Read moreBTG reiterates full-year guidance
29th Jan 2014 07:38
- Underlines full-year revenue guidance - Trading year-to-date in with expectations - Full-year revenue range of 275m to 285m pounds FTSE-250 healthcare company BTG said trading for the four months to January 28th has been in line with expectations as it reiterated full-year revenue guidance. The
Read moreFriday broker round-up UPDATE
24th Jan 2014 08:35
Aberdeen Asset Management: Morgan Stanley reduces target price from 492p to 393p and downgrades from equal-weight to underweight. Afren: Morgan Stanley moves target price from 210p to 220p retaining an overweight rating. Ashmore Group: Morgan Stanley cuts target price from 410p to 365p and reitera
Read moreBroker tips: Retailers, BTG, Bovis Homes
2nd Jan 2014 11:23
Analysts at Numis Securities reassured retail investors on Thursday that Debenhams' woes are not indicative of trends across the wider industry after its profit warnings earlier this week. They said they are confident that the strong updates from department store peers John Lewis and House of Frase
Read moreBroker snap: BTG overvalued after FDA rejects MS treatment
2nd Jan 2014 09:40
N+1 Singer has maintained its 'sell' recommendation for healthcare group BTG on concerns that partners Sanofi and Genzyme may not go ahead with their new Multiple Sclerosis (MS) drug Lemtrada in the US. The Food and Drug Administration (FDA) has sent a 'Complete Response Letter' to Sanofi regarding
Read moreThursday broker round-up UPDATE
19th Dec 2013 08:27
AstraZeneca: Alphavalue lowers target price from 3169p to 3087.7p and downgrades from reduce to sell. British American Tabacco: Panmure Gordon reduces target price from 3800p to 3200p and downgrades from buy to hold. Britvic: Investec ups target price from 600p to 672p and maintains a hold recomme
Read moreTuesday broker round-up UPDATE
17th Dec 2013 08:14
Advanced Medical Solutions: Panmure Gordon downgrades from buy to hold with a target price of 102p. Antofagasta: Canaccord Genuity cuts target price from 1110p to 1035p, while staying with its buy recommendation. ASOS: Panmure Gordon increases target price from 5950p to 6126p, while downgrading fr
Read moreWednesday broker round-up UPDATE
27th Nov 2013 09:14
Aviva: Nomura moves target price from 474p to 489p retaining a buy recommendation. Bellway: Numis upgrades to buy with a target price of 1690p. Breedon Aggregates: Jefferies starts with a target price of 42p and a buy recommendation. Britvic: UBS ups target price from 575p to 600p and keeps a neu
Read moreFTSE 250 movers: BTG makes strong gains after FDA approval
26th Nov 2013 13:30
Healthcare company BTG was in the top spot after revealing it has received approval from the US Food and Drug Administration for its Varithena treatment. Varithena, which previously went under the name of Varisolve, is used to treat varicose veins, which can cause a range of unpleasant and painful s
Read moreBTG given approval for varicose vein treatment by FDA
26th Nov 2013 11:45
Healthcare company BTG has received approval from the US Food and Drug Administration (FDA) for its Varithena treatment. Varithena, which previously went under the name of Varisolve, is used to treat varicose veins, which can cause a range of symptoms. Current treatments for varicose veins inclu
Read moreLondon midday: Stocks fall as investors await US data
26th Nov 2013 11:28
- Thanksgiving holiday to affect trading volumes - BTG jumps after Varithena approval - De La Rue, Mitchells & Butlers, Britvic gain after results - Glencore Xstrata drops on Las Bambas developments techMARK 2,652.61 +0.05% FTSE 100 6,663.62 -0.46% FTSE 250 15,343.14 +0.28% UK stocks headed slight
Read more